Maria Gracia-Hernandez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Gracia-Hernandez has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Duane H. Hamilton
Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
8 shared publications - Jeffrey Schlom
Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
8 shared publications - Maria del Mar Maldonado
Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
8 shared publications - Alejandro Villagra
Georgetown University, Lombardi Comprehensive Cancer Center
4 shared publications - Anatoly Dritschilo
Radiation Medi-cine; and
3 shared publications - Christian Zevallos-Delgado
University of Houston, Department of Biomedical Engineering, Houston, Texas, United States
3 shared publications
Latest Publications
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Endogenous retroviruses (ERV) are the genetic remnants of retroviruses in which proviral sequences integrated into germline cells of our ancestors. Although the vast majority of ERV sequences have accumulated mutations over the course of human evolution, some still contain open reading frames encoding full-length retroviral proteins. These sequences are typically epigenetically silenced in healthy adult human tissues. However, epigenetic dysregulation in cancer results in aberrant expression of ERVs in multiple cancer types. Therefore, ERVs represent a class of attractive therapeutic targets in cancer due to their immunogenicity and high expression in cancer cells compared with healthy tissues. In this review, we summarize the roles of ERVs in cancer and their immunogenicity, highlight the most recent advances in ERV-targeting strategies, discuss their challenges, and examine potential combination approaches that could further enhance the antitumor efficacy of ERV-targeting vaccines.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Endogenous retroviruses (ERV) are the genetic remnants of retroviruses in which proviral sequences integrated into germline cells of our ancestors. Although the vast majority of ERV sequences have accumulated mutations over the course of human evolution, some still contain open reading frames encoding full-length retroviral proteins. These sequences are typically epigenetically silenced in healthy adult human tissues. However, epigenetic dysregulation in cancer results in aberrant expression of ERVs in multiple cancer types. Therefore, ERVs represent a class of attractive therapeutic targets in cancer due to their immunogenicity and high expression in cancer cells compared with healthy tissues. In this review, we summarize the roles of ERVs in cancer and their immunogenicity, highlight the most recent advances in ERV-targeting strategies, discuss their challenges, and examine potential combination approaches that could further enhance the antitumor efficacy of ERV-targeting vaccines.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Table 4 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Preclinical studies using ERV-targeting vaccines in cancer models.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 4 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Preclinical studies using ERV-targeting vaccines in cancer models.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
The ISD within the retroviral ENV protein is conserved among ERVs from different species, as seen in murine leukemia virus (MLV), feline leukemia virus (FLV), and human ERVs, such as HERV-E clone 4-1. Expression of the retroviral ENV protein increases immunosuppression by inhibiting lymphocyte proliferation and decreasing activation of monocytes, T cells, and NK cells that could further contribute to tumor progression. Image modified from previous literature (Cianciolo et al., ref. 86. Reprinted with permission from American Association for the Advancement of Science). Created with BioRender.com. Maldonado Montalban, M. (2025) https://BioRender.com/w77o051.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
The ISD within the retroviral ENV protein is conserved among ERVs from different species, as seen in murine leukemia virus (MLV), feline leukemia virus (FLV), and human ERVs, such as HERV-E clone 4-1. Expression of the retroviral ENV protein increases immunosuppression by inhibiting lymphocyte proliferation and decreasing activation of monocytes, T cells, and NK cells that could further contribute to tumor progression. Image modified from previous literature (Cianciolo et al., ref. 86. Reprinted with permission from American Association for the Advancement of Science). Created with BioRender.com. Maldonado Montalban, M. (2025) https://BioRender.com/w77o051.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
ERV protein expression in multiple human cancer types.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
ERV protein expression in multiple human cancer types.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Percentages of ERV sequences expressed in different cancer types according to CancerHERVdb database (43).
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Percentages of ERV sequences expressed in different cancer types according to CancerHERVdb database (43).
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Immune responses against ERVs in patients with cancer.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Immune responses against ERVs in patients with cancer.
- Open Access
- 19 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 13 (6) , 792-803
Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Endogenous retroviruses (ERV) are the genetic remnants of retroviruses in which proviral sequences integrated into germline cells of our ancestors. Although the vast majority of ERV sequences have accumulated mutations over the course of human evolution, some still contain open reading frames encoding full-length retroviral proteins. These sequences are typically epigenetically silenced in healthy adult human tissues. However, epigenetic dysregulation in cancer results in aberrant expression of ERVs in multiple cancer types. Therefore, ERVs represent a class of attractive therapeutic targets in cancer due to their immunogenicity and high expression in cancer cells compared with healthy tissues. In this review, we summarize the roles of ERVs in cancer and their immunogenicity, highlight the most recent advances in ERV-targeting strategies, discuss their challenges, and examine potential combination approaches that could further enhance the antitumor efficacy of ERV-targeting vaccines.
- 19 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 13 (6) , 792-803
Open AccessCombination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Endogenous retroviruses (ERV) are the genetic remnants of retroviruses in which proviral sequences integrated into germline cells of our ancestors. Although the vast majority of ERV sequences have accumulated mutations over the course of human evolution, some still contain open reading frames encoding full-length retroviral proteins. These sequences are typically epigenetically silenced in healthy adult human tissues. However, epigenetic dysregulation in cancer results in aberrant expression of ERVs in multiple cancer types. Therefore, ERVs represent a class of attractive therapeutic targets in cancer due to their immunogenicity and high expression in cancer cells compared with healthy tissues. In this review, we summarize the roles of ERVs in cancer and their immunogenicity, highlight the most recent advances in ERV-targeting strategies, discuss their challenges, and examine potential combination approaches that could further enhance the antitumor efficacy of ERV-targeting vaccines.
- Open Access
- 13 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011378
Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
Background Endogenous retroviruses (ERVs) are remnants of retrovirus germline infections that occurred over the course of evolution and constitute between 5% and 8% of the human genome. While ERVs tend to be epigenetically silenced in normal adult human tissues, they are often overexpressed in carcinomas and may represent novel immunotherapeutic targets. This study characterizes the ERV envelope protein ERVMER34-1 as a target for a therapeutic cancer vaccine. Methods The expression of ERVMER34-1 in multiple healthy adult and cancer tissues was assessed, as was its immunogenicity, to ascertain whether specific T cells could lyse human carcinoma cell lines expressing ERVMER34-1. Furthermore, the ability of a rationally designed ERVMER34-1-targeted therapeutic vaccine to induce tumor clearance in two murine carcinoma models expressing ERVMER34-1 was examined either as a monotherapy or in combination with anti-programmed cell death protein-1/programmed death-ligand 1 monoclonal antibody (mAb) or the interleukin-15 superagonist N-803. Results The ERVMER34-1 protein was shown to be overexpressed in 232/376 of human carcinomas analyzed while being absent in most healthy adult tissues. High levels of ERVMER34-1 RNA expression associate with decreased survival in uveal melanoma, adenoid cystic, and head and neck carcinomas. ERVMER34-1-specific T cells were detected in peripheral blood mononuclear cells (PBMCs) of patients with cancer but not healthy donors following an overnight stimulation. However, reactive T cells are readily expanded from both healthy donor and patient with cancer PBMCs following a 7- day in vitro stimulation. Furthermore, ERVMER34-1-specific T cells selectively kill human carcinoma cell lines expressing ERVMER34-1. A novel, rationally designed, therapeutic cancer vaccine targeting ERVMER34-1 mediated tumor control in established syngeneic murine tumors expressing the full-length ERVMER34-1 protein. When combined with checkpoint blockade, the vaccine promoted expansion of neoepitope-reactive T cells whose function was further enhanced when combined with N-803. This expansion of neoepitope-reactive T cells was associated with tumor control. Conclusions This study reveals the potential of a vaccine that targets the retroviral envelope protein ERVMER34-1 and supports its continued development toward clinical testing as a new class of therapeutic cancer vaccine.
- 13 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011378
Open AccessCombination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
Background Endogenous retroviruses (ERVs) are remnants of retrovirus germline infections that occurred over the course of evolution and constitute between 5% and 8% of the human genome. While ERVs tend to be epigenetically silenced in normal adult human tissues, they are often overexpressed in carcinomas and may represent novel immunotherapeutic targets. This study characterizes the ERV envelope protein ERVMER34-1 as a target for a therapeutic cancer vaccine. Methods The expression of ERVMER34-1 in multiple healthy adult and cancer tissues was assessed, as was its immunogenicity, to ascertain whether specific T cells could lyse human carcinoma cell lines expressing ERVMER34-1. Furthermore, the ability of a rationally designed ERVMER34-1-targeted therapeutic vaccine to induce tumor clearance in two murine carcinoma models expressing ERVMER34-1 was examined either as a monotherapy or in combination with anti-programmed cell death protein-1/programmed death-ligand 1 monoclonal antibody (mAb) or the interleukin-15 superagonist N-803. Results The ERVMER34-1 protein was shown to be overexpressed in 232/376 of human carcinomas analyzed while being absent in most healthy adult tissues. High levels of ERVMER34-1 RNA expression associate with decreased survival in uveal melanoma, adenoid cystic, and head and neck carcinomas. ERVMER34-1-specific T cells were detected in peripheral blood mononuclear cells (PBMCs) of patients with cancer but not healthy donors following an overnight stimulation. However, reactive T cells are readily expanded from both healthy donor and patient with cancer PBMCs following a 7- day in vitro stimulation. Furthermore, ERVMER34-1-specific T cells selectively kill human carcinoma cell lines expressing ERVMER34-1. A novel, rationally designed, therapeutic cancer vaccine targeting ERVMER34-1 mediated tumor control in established syngeneic murine tumors expressing the full-length ERVMER34-1 protein. When combined with checkpoint blockade, the vaccine promoted expansion of neoepitope-reactive T cells whose function was further enhanced when combined with N-803. This expansion of neoepitope-reactive T cells was associated with tumor control. Conclusions This study reveals the potential of a vaccine that targets the retroviral envelope protein ERVMER34-1 and supports its continued development toward clinical testing as a new class of therapeutic cancer vaccine.
- Open Access
- 1 December 2023
- Published by American Association for Cancer Research (AACR)
Data from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
Radiotherapy is a curative cancer treatment modality that imparts damage to cellular DNA, induces immunogenic cell death, and activates antitumor immunity. Despite the radiotherapy-induced direct antitumor effect seen within the treated volume, accumulating evidence indicates activation of innate antitumor immunity. Acute proinflammatory responses mediated by anticancer M1 macrophages are observed in the immediate aftermath following radiotherapy. However, after a few days, these M1 macrophages are converted to anti-inflammatory and pro-cancer M2 phenotype, leading to cancer resistance and underlying potential tumor relapse. Histone deacetylase 6 (HDAC6) plays a crucial role in regulating macrophage polarization and innate immune responses. Here, we report targeting HDAC6 function with a novel selective inhibitor (SP-2-225) as a potential therapeutic candidate for combination therapy with radiotherapy. This resulted in decreased tumor growth and enhanced M1/M2 ratio of infiltrating macrophages within tumors. These observations support the use of selective HDAC6 inhibitors to improve antitumor immune responses and prevent tumor relapse after radiotherapy.
- 1 December 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
Radiotherapy is a curative cancer treatment modality that imparts damage to cellular DNA, induces immunogenic cell death, and activates antitumor immunity. Despite the radiotherapy-induced direct antitumor effect seen within the treated volume, accumulating evidence indicates activation of innate antitumor immunity. Acute proinflammatory responses mediated by anticancer M1 macrophages are observed in the immediate aftermath following radiotherapy. However, after a few days, these M1 macrophages are converted to anti-inflammatory and pro-cancer M2 phenotype, leading to cancer resistance and underlying potential tumor relapse. Histone deacetylase 6 (HDAC6) plays a crucial role in regulating macrophage polarization and innate immune responses. Here, we report targeting HDAC6 function with a novel selective inhibitor (SP-2-225) as a potential therapeutic candidate for combination therapy with radiotherapy. This resulted in decreased tumor growth and enhanced M1/M2 ratio of infiltrating macrophages within tumors. These observations support the use of selective HDAC6 inhibitors to improve antitumor immune responses and prevent tumor relapse after radiotherapy.
- Open Access
- 1 December 2023
- Published by American Association for Cancer Research (AACR)
Data from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
Radiotherapy is a curative cancer treatment modality that imparts damage to cellular DNA, induces immunogenic cell death, and activates antitumor immunity. Despite the radiotherapy-induced direct antitumor effect seen within the treated volume, accumulating evidence indicates activation of innate antitumor immunity. Acute proinflammatory responses mediated by anticancer M1 macrophages are observed in the immediate aftermath following radiotherapy. However, after a few days, these M1 macrophages are converted to anti-inflammatory and pro-cancer M2 phenotype, leading to cancer resistance and underlying potential tumor relapse. Histone deacetylase 6 (HDAC6) plays a crucial role in regulating macrophage polarization and innate immune responses. Here, we report targeting HDAC6 function with a novel selective inhibitor (SP-2-225) as a potential therapeutic candidate for combination therapy with radiotherapy. This resulted in decreased tumor growth and enhanced M1/M2 ratio of infiltrating macrophages within tumors. These observations support the use of selective HDAC6 inhibitors to improve antitumor immune responses and prevent tumor relapse after radiotherapy.
- 1 December 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
Radiotherapy is a curative cancer treatment modality that imparts damage to cellular DNA, induces immunogenic cell death, and activates antitumor immunity. Despite the radiotherapy-induced direct antitumor effect seen within the treated volume, accumulating evidence indicates activation of innate antitumor immunity. Acute proinflammatory responses mediated by anticancer M1 macrophages are observed in the immediate aftermath following radiotherapy. However, after a few days, these M1 macrophages are converted to anti-inflammatory and pro-cancer M2 phenotype, leading to cancer resistance and underlying potential tumor relapse. Histone deacetylase 6 (HDAC6) plays a crucial role in regulating macrophage polarization and innate immune responses. Here, we report targeting HDAC6 function with a novel selective inhibitor (SP-2-225) as a potential therapeutic candidate for combination therapy with radiotherapy. This resulted in decreased tumor growth and enhanced M1/M2 ratio of infiltrating macrophages within tumors. These observations support the use of selective HDAC6 inhibitors to improve antitumor immune responses and prevent tumor relapse after radiotherapy.